Management View - Champions Oncology reported record services revenue for the quarter, indicating strong performance in its service offerings [2] - The company achieved positive adjusted EBITDA for the third consecutive quarter, reflecting improved operational efficiency [2] - There is early momentum in the data business, suggesting potential for future growth and expansion in this segment [2]

Financial Data and Key Metrics Changes - Total revenue for the quarter was $16.6 million, a decrease of approximately 3% compared to $17 million in the prior year period [11] - Core study revenue reached a record $16.6 million, representing growth of approximately 32% from $12.6 million in the year-ago period [11] - Adjusted EBITDA for the quarter was $575,000, marking the third consecutive quarter of positive adjusted EBITDA [13] - GAAP loss from operations for the quarter was approximately $275,000 [13] - Gross margin for the quarter was 47%, down from 61% in the prior year period [13] Business Line Data and Key Metrics Changes - The core translational oncology services platform demonstrated strong performance, with record services revenue driven by effective study execution and conversion of previously booked work [3][11] - Data revenue was not recognized in the third quarter, compared to $4.5 million in the prior year period, contributing to the overall year-over-year revenue decline [12] - The company anticipates that data revenue will become a more meaningful contributor over time as the platform develops [12] Market Data and Key Metrics Changes - The company noted that customer budgets are stabilizing, leading to improved bookings converting into revenue [3] - There is a healthy underlying demand for the company's services, with expectations for revenue normalization as studies progress [4] Company Strategy and Development Direction - The company is focused on balancing growth and investment while maintaining positive adjusted EBITDA [5] - Investments are being made in both the data platform and the therapeutic subsidiary, Corellia, without diluting shares [5][9] - The company aims to maximize shareholder value across its differentiated tumor bank, radiopharmaceutical capabilities, and therapeutic subsidiary [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year revenue growth and positive adjusted EBITDA while continuing to invest in growth drivers [5][10] - The company expects to see the payoff from current investments beginning in fiscal 2027, with more meaningful acceleration anticipated in fiscal 2028 [5][10] - Discussions regarding external funding for Corellia are ongoing, with positive feedback from potential partners [8][9] Other Important Information - The company ended the quarter with $7.1 million in cash and no debt, maintaining a cash balance within projected ranges [16] - Operating expenses increased to $7.2 million, reflecting strategic investments in R&D, sales, and marketing [15] Q&A Session Summary - There were no questions from participants during the Q&A session [17]

Financial Data and Key Metrics Changes - Total revenue for Q3 2026 was $16.6 million, a decrease of approximately 3% compared to $17 million in the prior year period [11] - Core study revenue reached a record $16.6 million, representing growth of approximately 32% from $12.6 million in the year-ago period [11] - Adjusted EBITDA for the quarter was $575 thousand, marking the third consecutive quarter of positive adjusted EBITDA [13] - GAAP loss from operations for the quarter was approximately $275 thousand [13] - Gross margin for the quarter was 47%, down from 61% in the prior year period [13] Business Line Data and Key Metrics Changes - The core translational oncology services platform demonstrated strong performance, with record services revenue driven by effective study execution and conversion of previously booked work [4] - Data revenue was not recognized in Q3 2026, compared to $4.5 million in the prior year period, contributing to the overall year-over-year revenue decline [12] - Operating expenses increased to $7.2 million from $5.3 million in the prior year, reflecting investments in strategic priorities [14] Market Data and Key Metrics Changes - The company noted that quarterly revenue can fluctuate due to the timing of study progression and completion, with strong conversion of previously booked work benefiting revenue in the current period [5] - The underlying demand for services remains healthy, with a focus on expanding the pipeline of future work through increased commercial engagement [5] Company Strategy and Development Direction - The company is focused on balancing growth and investment while maintaining positive adjusted EBITDA, with expectations for more meaningful acceleration in fiscal 2027 and 2028 [6][10] - The data business is beginning to show early momentum, with new deals closed during the quarter and additional revenue expected in Q4 [4][7] - Corellia, the target discovery subsidiary, is generating attractive data and is in discussions for potential external funding, which could redirect investments towards other growth initiatives [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year revenue growth and positive adjusted EBITDA while continuing to invest in the data business and Corellia [3][6] - The company is optimistic about the long-term potential of its data platform and therapeutic subsidiary, aiming to maximize shareholder value across all growth vectors [9] Other Important Information - The company ended the quarter with $7.1 million in cash and no debt, maintaining a cash balance within projected ranges [16] - The next earnings call is scheduled for July, where further updates on progress will be provided [18] Q&A Session Summary - There were no questions from participants during the Q&A session [17]

Revenue Performance - Oncology revenue for the three months ended January 31, 2026, was $16.6 million, a decrease of 2.8% from $17.0 million in the same period in 2025 [101]. - For the nine months ended January 31, 2026, oncology revenue totaled $45.6 million, an increase of 2.2% from $44.6 million in the same period in 2025 [101]. - Revenue from TOS data licenses was $0 for the three months ended January 31, 2026, compared to $4.5 million for the same period in 2025 [105]. Cost and Expense Analysis - Cost of oncology revenue increased by $2.2 million or 33.5% to $8.8 million for the three months ended January 31, 2026, compared to $6.6 million in the prior year [107]. - Research and development expenses for the three months ended January 31, 2026, were $2.3 million, an increase of 32.1% from $1.7 million in the same period in 2025 [108]. - Total costs and operating expenses for the three months ended January 31, 2026, were $16.8 million, an increase of 34.3% from $12.5 million in the prior year [100]. - Sales and marketing expenses increased to $2.7 million for the three months ended January 31, 2026, up 47.6% from $1.8 million in the same period in 2025 [111]. - General and administrative expenses rose to $3.0 million for the three months ended January 31, 2026, an increase of 24.1% from $2.4 million in the same period in 2025 [112]. - The increase in sales and marketing expenses was primarily driven by higher compensation expenses related to the expansion of the Company's commercial organization [111]. - General and administrative expenses were primarily attributed to higher compensation expenses associated with executive leadership changes and increased IT infrastructure costs [112]. Financial Position - The company had a net loss of $508,000 for the nine months ended January 31, 2026, compared to a net income of $6.5 million for the same period in 2025 [99]. - As of January 31, 2026, the company had cash of $7.1 million and an accumulated deficit of approximately $80.4 million [99]. - Net cash used in operating activities was $2.5 million for the nine months ended January 31, 2026, compared to net cash provided of $518,000 in the same period in 2025 [113]. - Net cash used in investing activities was approximately $302,000 for the nine months ended January 31, 2026, compared to $136,000 in the same period in 2025 [114]. - Net cash provided by financing activities was $118,000 for the nine months ended January 31, 2026, down from $202,000 in the same period in 2025 [115]. - The Company has no off-balance sheet debt or similar obligations [118]. Strategic Outlook - The company expects that transitioning radiolabeling work into its laboratories will lead to a more favorable cost structure in the coming quarters [107]. - The company is evaluating strategic options to create additional value from its drug discovery business, which may include potential spin-out transactions or capital raises [98]. Accounting and Reporting - There have been no changes to critical accounting policies during the nine months ended January 31, 2026 [117]. - The Company is classified as a smaller reporting company and is not required to provide additional market risk disclosures [119].

Revenue Performance - Record study service revenue of $16.6 million, up approximately 32% year over year[4] - Total revenue of $16.6 million, a decrease of 2.8% compared to $17.0 million in the prior-year period[6] - Oncology revenue for the three months ended January 31, 2026, was $16.559 million, a decrease from $17.039 million in the same period of 2025, representing a decline of approximately 2.8%[29] Expenses and Costs - Cost of oncology revenue increased to $8.8 million, up 33.5% compared to $6.6 million in the same quarter last year[9] - Total costs and operating expenses for the quarter were $16.8 million, an increase of 34.3% compared to $12.5 million in the prior year[7] - Research and development expense increased by 32.1% to $2.3 million compared to $1.7 million in the prior year[10] - Sales and marketing expense rose by 47.6% to $2.7 million compared to $1.8 million in the prior year[10] - The cost of oncology revenue increased to $8.834 million for the three months ended January 31, 2026, compared to $6.617 million in the same period of 2025, indicating a rise of approximately 33.5%[29] - Research and development expenses increased to $2.271 million for the three months ended January 31, 2026, compared to $1.719 million in the same period of 2025, representing a rise of approximately 32.2%[29] Profitability and Earnings - Adjusted EBITDA of $574,000, down from $5.1 million in the same quarter last year[8] - For the three months ended January 31, 2026, the company reported a GAAP basic EPS of $(0.02), compared to $0.33 in the same period of 2025, reflecting a significant decline[28] - The adjusted EPS (diluted, Non-GAAP) for the three months ended January 31, 2026, was $0.04, down from $0.36 in the same period of 2025[28] - The company reported a net loss of $(279) thousand for the three months ended January 31, 2026, compared to a net income of $4.495 million in the same period of 2025[29] Cash Flow and Financial Position - Net cash used in operating activities was approximately $1.4 million for the quarter[11] - The company ended the quarter with cash on hand of approximately $7.1 million and no debt[12] - The company experienced a net cash used in operating activities of $(2.474) million for the nine months ended January 31, 2026, compared to a net cash provided of $518 thousand in the same period of 2025[31] Assets and Liabilities - Total assets decreased to $28.447 million as of January 31, 2026, down from $32.344 million as of April 30, 2025, reflecting a decline of approximately 12.1%[30] - Total liabilities decreased to $24.069 million as of January 31, 2026, compared to $28.572 million as of April 30, 2025, indicating a reduction of approximately 15.7%[30] Margin Analysis - Oncology services margin for the quarter was 47%, down from 61% for the same period last year[9] - The oncology services margin (Non-GAAP) for the three months ended January 31, 2026, was 47%, down from 61% in the same period of 2025[28]

Core Insights - The company anticipates introducing a new revenue stream through data-licensing, which is expected to positively impact revenue, margins, and enterprise value [1] - The wholly-owned drug development subsidiary, Corellia, is actively seeking capital and remains optimistic about its developed targets and compounds [1] - The company has built a rich multi-omic data set that enhances drug discovery and development, with increasing demand due to advancements in AI [2] Financial Performance - The company reported revenue of $13.5 million for Q2, a 17% increase year-over-year, and achieved income from operations of $700,000 compared to a loss of $1.9 million in the prior year [6] - Adjusted EBITDA for the quarter was $1.1 million, a significant improvement from an adjusted loss of $1.4 million in the same period last year [7] - Total revenue for the first half of the year was $27.6 million, reflecting a 14% increase compared to the first half of 2024 [10] Cost Management - The total cost of sales increased to $7.4 million, primarily due to rising mouse costs associated with growing study numbers [7] - R&D expenses were reduced to approximately $1.7 million, down from $2.5 million in the previous year, indicating a strategic focus on bottom-line results [8][9] - General and administrative expenses decreased to $1.6 million from $2.1 million, attributed to reduced compensation and recruitment costs [10] Market Dynamics - The funding environment is improving, with cautious optimism regarding investments from both big pharma and the biotech sector [14] - The company is focusing on leveraging its unique data assets, which are increasingly valuable in the current market landscape [15][16] Future Outlook - The company expects a slight decline in research service revenues next quarter, with a reacceleration anticipated in Q4 and into fiscal 2026 [13] - Revenue growth for fiscal 2025 is projected to be between 10% and 15%, supported by the new data revenue stream [13] - The company is confident in its growth trajectory and plans to provide further updates in the upcoming quarterly report [20]

Core Insights - Champions Oncology, Inc. (CSBR) is a significant entity in translational oncology research, providing R&D solutions to biopharmaceutical companies using patient-derived xenograft models [1] Financial Performance - On December 15, 2025, CSBR reported earnings per share (EPS) of $0.01, below the estimated $0.08, with actual revenue of $15 million, short of the estimated $16.42 million [2][6] - The oncology services segment achieved a profit of $7.8 million with a margin of 52%, indicating strong performance [3][6] - For the first half of fiscal 2026, total revenue rose by 5% to $29 million, with oncology services profit at $13.8 million and an adjusted EBITDA of $962,000 [4] Revenue Highlights - CSBR achieved record quarterly service revenue of $14.9 million in Q2 2026, marking an 11% increase in total revenue to $15 million [2][6] Valuation Metrics - The company has a price-to-earnings (P/E) ratio of approximately 44.63, indicating a high valuation relative to earnings, and a price-to-sales ratio of 2.50 [5]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Financial Data and Key Metrics Changes - Total revenue for Q2 2026 was $15 million, an increase of 11% year-over-year from $13.5 million in Q2 2025, driven by improved conversion of booked work due to a lower level of cancellations [8][9] - Income from operations for the quarter was $185,000, and adjusted EBITDA was approximately $800,000, with the company on track to achieve full-year positive adjusted EBITDA [8][9] - Gross margin improved to 52% compared to 45% in the previous year, supported by flat cost of sales despite increased revenue [9] Business Line Data and Key Metrics Changes - The company reported continued success in radiolabeling and radiopharmaceutical support workflows, which are expected to become a more significant part of the service offering over time [4][5] - Investments in the data platform are ongoing, enhancing its functionality and expanding utility for pharma partners, which is viewed as a critical long-term value driver [5][6] Market Data and Key Metrics Changes - The broader environment shows gradual improvement across pharma and biotech budgets, with customer engagement and opportunity pipeline generation improving relative to the previous year and a half [3] - A recent survey indicated that over a third of biotech executives plan to increase outsourcing next year, suggesting a positive trend for the company's services [15] Company Strategy and Development Direction - The company aims to deliver year-on-year revenue growth, invest in growth levers like data platforms, and maintain fiscal discipline to avoid shareholder dilution [2][3] - Focus remains on execution, maximizing conversion of existing bookings, improving operational efficiency, and advancing capabilities to distinguish the company in the market [3][7] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for booking momentum in the next calendar year as R&D budgets reset for 2026 [3] - The company is encouraged by improved operational discipline, a strengthening commercial position, and strategic investments in areas with competitive advantages [7][11] Other Important Information - Corelia, a wholly-owned subsidiary focused on target discovery, is making progress in discussions with potential venture capital funding partners, with plans to redirect investment dollars toward accelerating growth in the data business once funding is secured [6] Q&A Session Summary Question: Has there been an uptick in inbound call volume regarding RFPs, and how quickly can the company return to double-digit revenue growth? - Management noted optimism regarding opportunity generation and improvements in the market, with investments in the commercial team positioning the company well for recovery [15] Question: Are sales and marketing investments targeting the data opportunity exclusively? - Management highlighted a recent hire to lead the data business, emphasizing the strategic mindset and domain expertise brought to the team, which will support both data and other services [16] Question: What are the expectations for gross margins moving forward? - Management indicated that gross margins for the service business are expected to remain in the 50%-52% range, with potential fluctuations due to various expenses [19][20] Question: Can the company provide updates on Corelia's drug candidates and potential valuations? - Management refrained from sharing specific details about Corelia but expressed excitement about the data and traction with venture capital partners [22]

Financial Data and Key Metrics Changes - Total revenue for Q2 2026 was $15 million, an increase of 11% year-over-year from $13.5 million, driven by improved conversion of booked work due to a lower level of cancellations [8][9] - Income from operations for the quarter was $185,000, and adjusted EBITDA was approximately $800,000, with the company on track to achieve full-year positive adjusted EBITDA [8][9] - Gross margin improved to 52% compared to 45% last year, supported by flat cost of sales despite increased revenue [9] Business Line Data and Key Metrics Changes - The company reported continued success in radiolabeling and radiopharmaceutical support workflows, which are becoming increasingly significant in oncology drug development [4][5] - Investments in the data platform are ongoing, enhancing its functionality and expanding utility for pharma partners, which is viewed as a critical long-term value driver [5][6] Market Data and Key Metrics Changes - The broader environment shows gradual improvement across pharma and biotech budgets, with customer engagement and opportunity pipeline generation improving relative to the previous year and a half [3] - A recent survey indicated that over a third of biotech executives plan to increase outsourcing next year, suggesting a positive trend for the company's services [15] Company Strategy and Development Direction - The company aims to deliver year-on-year revenue growth, invest in growth levers like data platforms, and maintain fiscal discipline to avoid shareholder dilution [2][3] - Focus remains on execution, maximizing conversion of existing bookings, improving operational efficiency, and advancing capabilities to distinguish the company in the market [3][7] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for booking momentum in the next calendar year as R&D budgets reset for 2026 [3] - The company is encouraged by improved operational discipline, a strengthening commercial position, and strategic investments in areas with competitive advantages [7][11] Other Important Information - The company ended the quarter with $8.5 million in cash and no debt, maintaining a solid financial position [10] - Corelia, a wholly-owned subsidiary focused on target discovery, is making progress in discussions with potential venture capital funding partners [6] Q&A Session Summary Question: Has there been an uptick in inbound call volume regarding RFPs, and how quickly can the company return to double-digit revenue growth? - Management noted optimism regarding opportunity generation and improvements in the market, with investments in the commercial team positioning the company well for recovery [15] Question: Are sales and marketing investments targeting the data opportunity exclusively? - Management highlighted a recent hire to lead the data business, emphasizing the strategic mindset and domain expertise brought to the team [16] Question: What are the expectations for gross margins moving forward? - Management indicated that gross margins for the service business are expected to remain in the 50%-52% range, with potential fluctuations due to various expenses [19][20] Question: Can the company provide updates on Corelia's drug candidates and potential valuations? - Management refrained from sharing specific details but expressed excitement about the data and traction with VC partners [22]